第1章 避妊薬・避妊具

第2章 排卵誘発剤・デバイス

第3章 企業プロファイル

Actavis, Inc.

Bayer AG

Ferring Pharmaceuticals A/S

Johnson & Johnson

Merck & Company, Inc.

Merck KGaA

Teva Pharmaceuticals/Teva Pharmaceutical Industries Ltd.

付録

目次

Product Code: A471

The U.S. market for reproductive management products is large and robust,
estimated at more than $3.7 billion in 2013. This market, which includes a
broad range of contraceptive drugs, contraceptive devices/implants, and
fertility drugs, is expected to expand at a healthy compound annual growth
rate of more than 7%, increasing by more than $1.5 billion over a span of 5
years.

Despite a sluggish economy, intense competition, pricing pressures,
litigation, and the significant impact of generic contraceptives, growth in
this market is expected to accelerate at a better than average pace throughout
the forecast period, as the contraceptives segment, in particular, benefits
from highly positive insurance reimbursement (as a result of the 2010
Affordable Care Act) and increasing consumer affordability. The contraceptives
market is also expected to flourish due to the introduction of several safer,
more tolerable, lower-dosage, yet highly effective contraceptive drugs, and
strong advertising/marketing efforts by major pharmaceutical firms.
Additionally, the market is benefiting from increased consumer preference and
usage of novel contraceptive devices and implants, which provide a convenient,
long-term alternative for preventing pregnancy, especially in women who cannot
tolerate, or fail to adhere to required dosing schedules of oral drug
therapies.

The U.S. market for reproductive management products will also benefit from
continued strong demand for easier-to-use, highly effective fertility drugs,
as well as the introduction of new technologies, which are expected to enhance
assisted reproductive technology and further improve pregnancy rates and
decrease potential side effects.

Overall, the U.S. market for reproductive management products will continue to
benefit from the stability and growth of the aging female population in the
U.S., which continues to postpone or refrain from childbearing and demand
access to highly effective contraceptives and fertility drugs.